Henan Newland Pharmaceutical Co. Ltd. A (301277) - Total Liabilities
Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) has total liabilities worth CN¥257.50 Million CNY (≈ $37.68 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Henan Newland Pharmaceutical Co. Ltd. A to assess how effectively this company generates cash.
Henan Newland Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check 301277 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Henan Newland Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
China | CN¥660.65 Million |
|
Latent View Analytics Limited
NSE:LATENTVIEW
|
India | Rs2.44 Billion |
|
Sichuan Expressway Company Limited
F:EXF1
|
Germany | €42.46 Billion |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
China | CN¥536.28 Million |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
China | CN¥305.35 Million |
|
Sinostar Cable Co. Ltd.
SHE:300933
|
China | CN¥2.22 Billion |
|
Shenzhen Jinxinnong Feed Co Ltd
SHE:002548
|
China | CN¥3.97 Billion |
|
Zhejiang Jasan Holding Group Co Ltd
SHG:603558
|
China | CN¥1.57 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Henan Newland Pharmaceutical Co. Ltd. A market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Newland Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Newland Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥270.69 Million ≈ $39.61 Million |
+69.16% |
| 2023-12-31 | CN¥160.02 Million ≈ $23.42 Million |
-8.34% |
| 2022-12-31 | CN¥174.58 Million ≈ $25.55 Million |
-33.24% |
| 2021-12-31 | CN¥261.53 Million ≈ $38.27 Million |
+25.39% |
| 2020-12-31 | CN¥208.57 Million ≈ $30.52 Million |
-- |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naph… Read more